Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombotic Thrombocytopenic | 6 | 2018 | 12 | 0.930 |
Why?
|
| Platelet Activating Factor | 4 | 2007 | 15 | 0.740 |
Why?
|
| ADAM Proteins | 3 | 2012 | 12 | 0.700 |
Why?
|
| Apolipoprotein A-I | 5 | 2012 | 64 | 0.580 |
Why?
|
| Plasma Exchange | 2 | 2018 | 13 | 0.450 |
Why?
|
| Oxymorphone | 1 | 2014 | 9 | 0.420 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2014 | 8 | 0.420 |
Why?
|
| Mass Spectrometry | 3 | 2006 | 98 | 0.330 |
Why?
|
| Neutrophils | 4 | 2007 | 120 | 0.320 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2008 | 1 | 0.290 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 9 | 0.280 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2008 | 3 | 0.280 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 83 | 0.280 |
Why?
|
| Myocardium | 1 | 2008 | 184 | 0.270 |
Why?
|
| Heart Diseases | 1 | 2008 | 114 | 0.260 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2006 | 2 | 0.250 |
Why?
|
| Blood Coagulation Disorders | 1 | 2006 | 11 | 0.250 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 40 | 0.250 |
Why?
|
| Myocardial Infarction | 2 | 2008 | 466 | 0.250 |
Why?
|
| Hematoma | 1 | 2006 | 26 | 0.250 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 17 | 0.240 |
Why?
|
| Humans | 23 | 2018 | 32284 | 0.230 |
Why?
|
| Clinical Chemistry Tests | 1 | 2004 | 1 | 0.220 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2004 | 7 | 0.220 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 15 | 0.210 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 10 | 0.210 |
Why?
|
| Thrombosis | 1 | 2004 | 78 | 0.210 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 264 | 0.200 |
Why?
|
| Cholesterol | 4 | 2012 | 262 | 0.180 |
Why?
|
| Membrane Microdomains | 2 | 2012 | 22 | 0.170 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 58 | 0.170 |
Why?
|
| Female | 12 | 2018 | 19947 | 0.160 |
Why?
|
| Autoimmunity | 2 | 2010 | 31 | 0.150 |
Why?
|
| Lipoproteins, HDL | 2 | 2012 | 250 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2016 | 61 | 0.140 |
Why?
|
| Male | 9 | 2014 | 19443 | 0.130 |
Why?
|
| Middle Aged | 7 | 2014 | 11853 | 0.130 |
Why?
|
| Mixed Function Oxygenases | 2 | 2008 | 12 | 0.130 |
Why?
|
| Obesity | 1 | 2003 | 1111 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 10 | 0.120 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2016 | 9 | 0.120 |
Why?
|
| Diet, Atherogenic | 3 | 2011 | 74 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 27 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 96 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 140 | 0.110 |
Why?
|
| Dapsone | 1 | 2014 | 5 | 0.100 |
Why?
|
| Anemia, Hemolytic | 1 | 2014 | 8 | 0.100 |
Why?
|
| Atherosclerosis | 2 | 2011 | 820 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2014 | 30 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 6 | 2016 | 792 | 0.100 |
Why?
|
| Adult | 4 | 2014 | 9259 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 556 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 504 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2014 | 159 | 0.090 |
Why?
|
| Plasmapheresis | 1 | 2012 | 11 | 0.090 |
Why?
|
| Macrophages | 2 | 2010 | 207 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2012 | 66 | 0.090 |
Why?
|
| Immunosuppression | 1 | 2012 | 118 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2011 | 47 | 0.090 |
Why?
|
| Recurrence | 1 | 2012 | 285 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 61 | 0.080 |
Why?
|
| Mice | 6 | 2016 | 2571 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 30 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 34 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 248 | 0.080 |
Why?
|
| Plasmids | 2 | 2008 | 50 | 0.080 |
Why?
|
| Methods | 1 | 2008 | 12 | 0.070 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2008 | 4 | 0.070 |
Why?
|
| Necrosis | 1 | 2008 | 54 | 0.070 |
Why?
|
| von Willebrand Factor | 1 | 2008 | 16 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 54 | 0.070 |
Why?
|
| Automation | 1 | 2008 | 28 | 0.070 |
Why?
|
| Troponin I | 1 | 2008 | 20 | 0.070 |
Why?
|
| Aortic Diseases | 1 | 2009 | 62 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 37 | 0.070 |
Why?
|
| Risk Factors | 2 | 2008 | 3934 | 0.070 |
Why?
|
| Factor VII | 1 | 2008 | 4 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2008 | 3628 | 0.070 |
Why?
|
| Protein Engineering | 1 | 2008 | 19 | 0.070 |
Why?
|
| Acetyltransferases | 2 | 2005 | 3 | 0.070 |
Why?
|
| Lipids | 2 | 2010 | 253 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 48 | 0.070 |
Why?
|
| Animals | 8 | 2016 | 8199 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2005 | 33 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2005 | 138 | 0.070 |
Why?
|
| Copper | 1 | 2007 | 11 | 0.070 |
Why?
|
| Echocardiography | 1 | 2008 | 190 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 25 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 2649 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2005 | 250 | 0.060 |
Why?
|
| Deuterium | 1 | 2007 | 11 | 0.060 |
Why?
|
| Isotope Labeling | 1 | 2007 | 14 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 14 | 0.060 |
Why?
|
| Calibration | 1 | 2007 | 24 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 174 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 34 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 22 | 0.060 |
Why?
|
| Antifibrinolytic Agents | 1 | 2006 | 14 | 0.060 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2006 | 8 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3416 | 0.060 |
Why?
|
| DNA Primers | 1 | 2006 | 84 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 63 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2006 | 80 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2006 | 88 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 757 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 252 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 290 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 41 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 359 | 0.060 |
Why?
|
| Vitamin K | 1 | 2005 | 8 | 0.060 |
Why?
|
| Factor IX | 1 | 2005 | 11 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2003 | 456 | 0.060 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 13 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 33 | 0.060 |
Why?
|
| Osmotic Pressure | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 69 | 0.050 |
Why?
|
| Chromatography | 1 | 2004 | 4 | 0.050 |
Why?
|
| Glycerophospholipids | 1 | 2004 | 3 | 0.050 |
Why?
|
| Lysophosphatidylcholines | 1 | 2004 | 3 | 0.050 |
Why?
|
| Thrombocytosis | 1 | 2004 | 1 | 0.050 |
Why?
|
| Phenotype | 1 | 2006 | 622 | 0.050 |
Why?
|
| Pyridines | 1 | 2005 | 79 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 8 | 0.050 |
Why?
|
| Catalysis | 1 | 2004 | 71 | 0.050 |
Why?
|
| Imidazoles | 1 | 2005 | 97 | 0.050 |
Why?
|
| Factor VIII | 1 | 2004 | 20 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 108 | 0.050 |
Why?
|
| Time Factors | 2 | 2009 | 2205 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 299 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 184 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 273 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2005 | 255 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2002 | 4 | 0.050 |
Why?
|
| Receptors, Eicosanoid | 1 | 2002 | 5 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 65 | 0.050 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2002 | 49 | 0.050 |
Why?
|
| Factor V | 1 | 2002 | 5 | 0.050 |
Why?
|
| Continental Population Groups | 1 | 2003 | 228 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2002 | 33 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 43 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 657 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 94 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2002 | 226 | 0.040 |
Why?
|
| Aged | 3 | 2008 | 10265 | 0.040 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 99 | 0.040 |
Why?
|
| Aorta | 2 | 2011 | 125 | 0.040 |
Why?
|
| Receptors, LDL | 2 | 2010 | 66 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 94 | 0.040 |
Why?
|
| Lymphocyte Count | 2 | 2010 | 25 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1083 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2010 | 113 | 0.040 |
Why?
|
| Stroke | 1 | 2004 | 691 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 52 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 489 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2018 | 47 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2010 | 603 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 257 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 8 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2016 | 36 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 79 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 61 | 0.030 |
Why?
|
| Cell Line | 2 | 2008 | 454 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 2012 | 8 | 0.020 |
Why?
|
| Ceramides | 1 | 2012 | 10 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 75 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 110 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2012 | 100 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 42 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 87 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 36 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 235 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 93 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 66 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 80 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 346 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 46 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2010 | 84 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 181 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 121 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 2011 | 194 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 839 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2009 | 2 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 50 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 212 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 84 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 130 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 74 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 78 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 223 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 454 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 83 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 204 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 45 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 506 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2010 | 727 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 15 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 42 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 39 | 0.010 |
Why?
|
| Cricetinae | 1 | 2005 | 51 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 521 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1895 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2002 | 5 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 16 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2002 | 19 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2002 | 7 | 0.010 |
Why?
|
| Calcimycin | 1 | 2002 | 8 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 37 | 0.010 |
Why?
|
| Acyltransferases | 1 | 2002 | 18 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 43 | 0.010 |
Why?
|
| Phospholipases A | 1 | 2002 | 31 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 40 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 164 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 74 | 0.010 |
Why?
|
| Indoles | 1 | 2002 | 65 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 83 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 3 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2002 | 15 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 25 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 70 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 110 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2002 | 90 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 120 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 305 | 0.010 |
Why?
|
| Synapses | 1 | 2002 | 87 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 702 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 232 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 478 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 854 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 497 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 541 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 461 | 0.010 |
Why?
|